Cargando…

PD-1(T) TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC

PURPOSE: Durable clinical benefit to PD-1 blockade in non–small cell lung cancer (NSCLC) is currently limited to a small fraction of patients, underlining the need for predictive biomarkers. We recently identified a tumor-reactive tumor-infiltrating T lymphocyte (TIL) pool, termed PD-1(T) TILs, with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hummelink, Karlijn, van der Noort, Vincent, Muller, Mirte, Schouten, Robert D., Lalezari, Ferry, Peters, Dennis, Theelen, Willemijn S.M.E., Koelzer, Viktor H., Mertz, Kirsten D., Zippelius, Alfred, van den Heuvel, Michel M., Broeks, Annegien, Haanen, John B.A.G., Schumacher, Ton N., Meijer, Gerrit A., Smit, Egbert F., Monkhorst, Kim, Thommen, Daniela S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Precision Medicine and Imaging
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762332/ https://www.ncbi.nlm.nih.gov/pubmed/35852792 http://dx.doi.org/10.1158/1078-0432.CCR-22-0992

Ejemplares similares

A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small cell lung cancer treated with PD-1 blockade
por: Thommen, D.S., et al.
Publicado: (2018)

Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisions
por: Hummelink, Karlijn, et al.
Publicado: (2019)

Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers
por: Tas, Liselotte, et al.
Publicado: (2023)

Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
por: Mishra, Akhilesh, et al.
Publicado: (2023)

Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression
por: Lin, Ziying, et al.
Publicado: (2019)

Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma
por: Klemen, Nicholas D., et al.
Publicado: (2022)

PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours
por: Lamarca, Angela, et al.
Publicado: (2018)

Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions
por: Teng, Feifei, et al.
Publicado: (2016)

Predictive relevance of PD-L1 expression with pre-existing TILs in gastric cancer
por: Ju, Xiaoli, et al.
Publicado: (2017)

Classification of gallbladder cancer by assessment of CD8(+) TIL and PD-L1 expression
por: Lin, Jianzhen, et al.
Publicado: (2018)

Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
por: Caushi, Justina X., et al.
Publicado: (2021)

Concordance, Correlation, and Clinical Impact of Standardized PD-L1 and TIL Scoring in SCCHN
por: De Keukeleire, Stijn Jeroen, et al.
Publicado: (2022)

(18)F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition
por: Reeves, Kirsten M., et al.
Publicado: (2022)

Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
por: Harter, Patrick N., et al.
Publicado: (2015)

PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome
por: Bekos, Christine, et al.
Publicado: (2021)

Integrated functional and spatial profiling of tumour immune responses induced by immunotherapy: the iPROFILER platform
por: Koelzer, V.H., et al.
Publicado: (2021)

TIL classified to memory state are correlated with response to immune checkpoint blockade
por: Jedema, Inge, et al.
Publicado: (2022)

Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status
por: Hsu, Jim, et al.
Publicado: (2022)

PD-1/CTLA-4 Blockade Leads to Expansion of CD8(+)PD-1(int) TILs and Results in Tumor Remission in Experimental Liver Cancer
por: Bufe, Sandra, et al.
Publicado: (2022)

Fewer tumour-specific PD-1(+)CD8(+) TILs in high-risk “Infiltrating” HPV(−) HNSCC
por: Xu, Ke, et al.
Publicado: (2020)

Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
por: Caushi, Justina X., et al.
Publicado: (2021)

Uncovering PD-L1 and CD8(+) TILS Expression and Clinical Implication in Cervical Squamous Cell Carcinoma
por: Chen, Jingjing, et al.
Publicado: (2020)

Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma
por: Wang, Chao, et al.
Publicado: (2020)

Cellular Virotherapy Increases Tumor-Infiltrating Lymphocytes (TIL) and Decreases their PD-1(+) Subsets in Mouse Immunocompetent Models
por: Morales-Molina, Alvaro, et al.
Publicado: (2020)

Concordance of PD-L1 expression and CD8(+) TIL intensity between NSCLC and synchronous brain metastases
por: Batur, Sebnem, et al.
Publicado: (2020)

TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer
por: Yin, Huanhuan, et al.
Publicado: (2020)

Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of Breast Cancer Subtypes
por: Ni, Yunbi, et al.
Publicado: (2022)

PMS2 Expression With Combination of PD-L1 and TILs for Predicting Survival of Esophageal Squamous Cell Carcinoma
por: Jiang, Dongxian, et al.
Publicado: (2022)

PD-L1 and TILs expression and their association with clinicopathological characteristics in Vietnamese women with primary invasive breast cancer
por: Huynh, Chau Giang, et al.
Publicado: (2023)

Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer
por: Theelen, Willemijn S. M. E., et al.
Publicado: (2019)

Differential expression of PD-L1 and PD-L2 is associated with the tumor microenvironment of TILs and M2 TAMs and tumor differentiation in non-small cell lung cancer
por: Sumitomo, Ryota, et al.
Publicado: (2022)

Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma
por: Feng, Yong, et al.
Publicado: (2015)

Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma
por: Zhou, Xiang, et al.
Publicado: (2020)

Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer
por: Wang, Yumeng, et al.
Publicado: (2022)

PD-1 blockade upregulate TIM-3 expression as a compensatory regulation of immune check point receptors in HNSCC TIL
por: Shayan, Gulidanna, et al.
Publicado: (2015)

FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non‐small cell lung cancer
por: Theelen, Willemijn SME, et al.
Publicado: (2016)

Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer
por: Zhang, Libin, et al.
Publicado: (2021)

Clinical significance and correlation of PD-L1, B7-H3, B7-H4, and TILs in pancreatic cancer
por: Yang, Jiayue, et al.
Publicado: (2022)

PD-L1, CD4+, and CD8+ Tumor-Infiltrating Lymphocytes (TILs) Expression Profiles in Melanoma Tumor Microenvironment Cells
por: Caraban, Bogdan Marian, et al.
Publicado: (2023)

Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness
por: Lindenberg, Melanie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lntqgp34a9c82362mnqj0ok238